Αποτελέσματα Αναζήτησης
Κυριότερες Ειδήσεις
10 Οκτ 2024 · FDA also approved the FoundationOne Liquid CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with inavolisib with palbociclib and fulvestrant.
16 Νοε 2023 · FDA also approved the FoundationOne®CDx assay as a companion diagnostic device to identify patients with breast cancer for treatment with capivasertib with fulvestrant.
3 ημέρες πριν · by Lori Solomon. The U.S. Food and Drug Administration has approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine ...
10 Οκτ 2024 · Itovebi is approved for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after adjuvant endocrine therapy recurrence. The INAVO120 trial showed Itovebi improved progression-free survival to 15 months versus 7.3 months with placebo. The objective response rate was 58% with Itovebi compared to 25% with placebo, with a longer ...
17 Σεπ 2024 · Kisqali has been approved as a treatment for metastatic breast cancer (MBC) patients in 99 countries worldwide, including by the US FDA and the European Commission 1,2 6. In the US, Kisqali is indicated for the treatment of adults with HR+/HER2- advanced or MBC in combination with an AI as initial ET or fulvestrant as initial ET or following ...
10 Οκτ 2024 · Approval for Inavolisib Triplet Therapy Breast Cancer Based on Clinical Trial Results. But now the U.S. Food and Drug Administration (FDA) has approved a new three-drug combination treatment that appears to be very effective for these breast cancer patients. In a phase 3 clinical trial, the “triplet” therapy more than doubled progression ...
